Glioblastoma patients are still not cured by the treatments available at the moment. We investigated the therapeutic properties of temozolomide in combination with F16-IL2, a clinical-stage immunocytokine consisting of human interleukin (IL)-2 fused to the human antibody F16, specific to the A1 domain of tenascin-C.
Combination of temozolomide with immunocytokine F16-IL2 for the treatment of glioblastoma / M. Pedretti, C. Verpelli, J. Mårlind, G. Bertani, C. Sala, D. Neri, L. Bello. - In: BRITISH JOURNAL OF CANCER. - ISSN 0007-0920. - 103:6(2010 Sep 07), pp. 827-836. [10.1038/sj.bjc.6605832]
Combination of temozolomide with immunocytokine F16-IL2 for the treatment of glioblastoma
L. Bello
2010
Abstract
Glioblastoma patients are still not cured by the treatments available at the moment. We investigated the therapeutic properties of temozolomide in combination with F16-IL2, a clinical-stage immunocytokine consisting of human interleukin (IL)-2 fused to the human antibody F16, specific to the A1 domain of tenascin-C.
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
